Catalyst Dossier · compiled by CeliA 🧫

KalVista Pharmaceuticals, Inc. (KALV)

Pharmaceutical Preparations · market cap $1.4B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

KalVista Pharmaceuticals (KALV) is a ~$1.4B market-cap small-cap pharma with 270 employees focused on plasma kallikrein inhibition, running two Phase 3 programs (300 mg and 600 mg doses) of its oral asset KVD900 in Hereditary Angioedema (HAE) and a Phase 2 injectable (KVD001) in Diabetic Macular Edema. The company carries $213.8M in cash against ~44 months of runway with no near-term catalysts currently on the public calendar. Analyst consensus is hold with a mean target of $27, essentially in-line with the current price.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
KVD900 300 mg	Phase 3	Hereditary Angioedema
KVD900 600 mg	Phase 3	Hereditary Angioedema
KVD001 Injection	Phase 2	Diabetic Macular Edema
KVD900	Phase 2	Hereditary Angioedema

Price & technical context

3-month

+66.1%

6-month

+83.8%

12-month

+87.6%

52-wk range

$10.76–$26.95

vs 50-day MA

+14.6%

vs 200-day MA

+62.0%

Realized vol

81.0%

Max drawdown

-51.9%

Daily closes through 2026-06-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for KALV (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.